Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Astria Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ATXS
Nasdaq
8731
https://astriatx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Astria Therapeutics Inc
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
- Apr 9th, 2024 12:00 pm
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)
- Apr 3rd, 2024 11:00 pm
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 3rd, 2024 8:10 pm
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
- Mar 25th, 2024 11:30 am
Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the company
- Mar 23rd, 2024 2:37 pm
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
- Mar 4th, 2024 9:10 pm
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
- Feb 20th, 2024 1:00 pm
Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 1:00 pm
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc
- Jan 31st, 2024 12:29 am
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
- Jan 30th, 2024 2:08 pm
Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
- Nov 27th, 2023 1:00 pm
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
- Nov 25th, 2023 12:08 pm
Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference
- Nov 21st, 2023 1:00 pm
Astria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate Developments
- Nov 13th, 2023 4:07 pm
Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
- Nov 13th, 2023 1:00 pm
Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
- Nov 10th, 2023 1:00 pm
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
- Nov 9th, 2023 1:00 pm
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting
- Nov 3rd, 2023 12:10 pm
Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th
- Oct 30th, 2023 12:00 pm
Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 60% of the company
- Oct 15th, 2023 1:44 pm
Scroll